Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Department of Bioengineering, Rice University, Houston, TX, USA.
Oncotarget. 2022 Mar 9;13:521-533. doi: 10.18632/oncotarget.28215. eCollection 2022.
Osteosarcoma (OS) is a genetically diverse bone cancer that lacks a consistent targetable mutation. Recent studies suggest the IGF/PI3K/mTOR pathway and YAP/TAZ paralogs regulate cell fate and proliferation in response to biomechanical cues within the tumor microenvironment. How this occurs and their implication upon osteosarcoma survival, remains poorly understood. Here, we show that IGF-1R can translocate into the nucleus, where it may act as part of a transcription factor complex. To explore the relationship between YAP/TAZ and total and nuclear phosphorylated IGF-1R (pIGF-1R), we evaluated sequential tumor sections from a 37-patient tissue microarray by confocal microscopy. Next, we examined the relationship between stained markers, clinical disease characteristics, and patient outcomes. The nuclear to cytoplasmic ratios (N:C ratio) of YAP and TAZ strongly correlated with nuclear pIGF-1R (r = 0.522, = 0.001 for each pair). Kaplan-Meier analyses indicated that nuclear pIGF-1R predicted poor overall survival, a finding confirmed in the Cox proportional hazards model. Though additional investigation in a larger prospective study will be required to validate the prognostic accuracy of these markers, our results may have broad implications for the new class of YAP, TAZ, AXL, or TEAD inhibitors that have reached early phase clinical trials this year.
骨肉瘤(OS)是一种遗传多样性的骨癌,缺乏一致的靶向突变。最近的研究表明,IGF/PI3K/mTOR 途径和 YAP/TAZ 同源物调节细胞命运和增殖,以响应肿瘤微环境中的生物力学线索。这种情况如何发生及其对骨肉瘤生存的影响仍知之甚少。在这里,我们表明 IGF-1R 可以易位到细胞核,在那里它可能作为转录因子复合物的一部分发挥作用。为了探索 YAP/TAZ 与总和核磷酸化 IGF-1R(pIGF-1R)之间的关系,我们通过共聚焦显微镜评估了来自 37 名患者组织微阵列的连续肿瘤切片。接下来,我们检查了染色标记物与临床疾病特征和患者预后之间的关系。YAP 和 TAZ 的核质比(N:C 比)与核 pIGF-1R 强烈相关(r = 0.522,每对均为 = 0.001)。Kaplan-Meier 分析表明,核 pIGF-1R 预测总体生存率差,这一发现在 Cox 比例风险模型中得到证实。尽管需要在更大的前瞻性研究中进一步调查这些标记物的预后准确性,但我们的结果可能对今年进入早期临床阶段的 YAP、TAZ、AXL 或 TEAD 抑制剂等新型抑制剂具有广泛的意义。